In 2023, experts decided against adding obesity drugs to the World Health Organisation's essential medicines list.

The active ingredient in the popular weight loss drug Wegovy may help treat a type of fatty liver disease, according to a new study published Wednesday.

The U.S. Food and Drug Administration has accepted Novo Nordisk's marketing application for an oral version of its ...

Health Canada begins a priority review of semaglutide 2.4 mg, a weekly treatment by Novo Nordisk for MASH, a liver disease ...

More than a billion people now have obesity worldwide, according to the WHO, and around 70% of them live in low and ...

GLP-1 drug prices are falling. That's good news for patients, but perhaps not such good news for pharmaceutical stock ...